- US12458652utility2025Pharmaceutical Compositions of Spironolactone for Deep Dermal Drug Delivery0 cites
- US12453721utility2025Topical Roflumilast Aerosol Foams0 cites
- US12390453utility2025Method for Reducing Side Effects from Administration of Phosphodiesterase-4 Inhibitors0 cites
- US12336983utility2025Inhibition of Crystal Growth of Roflumilast0 cites
- US12329751utility2025Topical Roflumilast Formulation Having Antifungal Properties0 cites
- US12310956utility2025Topical Roflumilast Formulation Having Improved Delivery and Plasma Half-life0 cites
- US12257242utility2025Inhibition of Crystal Growth of Roflumilast0 cites
- US12220409utility2025Roflumilast Formulations with an Improved Pharmacokinetic Profile0 cites
- US12161643utility2024Stable Formulations of SHR03020 cites
- US12144802utility2024Pharmaceutical Compositions of Roflumilast and Solvents Capable of Dissolving High Amounts of the Drug0 cites
- US12083122utility2024Laureth-4 Containing Topical Formulations0 cites
- US12053481utility2024Compositions and Methods for Deep Dermal Drug Delivery0 cites
- US12042487utility2024Method for Reducing Side Effects from Administration of Phosphodiesterase-4 Inhibitors0 cites
- US12042558utility2024Method and Formulation for Improving Roflumilast Skin Penetration Lag Time0 cites
- US12016848utility2024Roflumilast Formulations with an Improved Pharmacokinetic Profile0 cites
- US12011437utility2024Roflumilast Formulations with an Improved Pharmacokinetic Profile0 cites
- US12005051utility2024Topical Roflumilast Formulation Having Improved Delivery and Plasma Half Life0 cites
- US12005052utility2024Topical Roflumilast Formulation Having Improved Delivery and Plasma Half-life0 cites
- US11992480utility2024Method for Reducing Side Effects from Administration of Phosphodiesterase-4 Inhibitors0 cites
- US11819496utility2023Topical Roflumilast Formulation Having Improved Delivery and Plasma Half-life0 cites
Page 1 of 2Next →